Matches in SemOpenAlex for { <https://semopenalex.org/work/W70642724> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W70642724 abstract "The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease. Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF). Therefore and in consideration of the promising response rates of the combination of IL-2, IFN-alpha and 5-FU [1] in metastatic renal cancer, we found it reasonable to test the combination of 5-FU and thalidomide. Thus, we conducted a phase I trial to determine safety, side effects and responses to such a treatment.Patients with metastasized renal cell cancer after nephrectomy and progress after IL-2 and interferon treatment, received oral 5-FU at a dose of 1250 mg/qm(2) twice a day for two weeks, then after pausing a week, the oral application was restarted. In addition, oral thalidomide was applied constantly at a maximum dose of 400 mg/d. The combined therapy was given for three months. The primary endpoint was duration until disease progression, the secondary endpoint the response to treatment. Response was determined by CT scans three months after the end of treatment.In total, 12 male patients participated in the trial and received the combined oral therapy. Concerning clinical response, one mixed response (8%), a stable disease in 4/12 patients (33%) and progression was seen in 7 patients (58%). The survival from the start of the therapy showed a median of 21 months with three patients being alive. At present, the longest survival after the therapy is 51 months.The combination of oral 5-FU and thalidomide showed clinical response with tolerable side effects. Further studies will be required to assess the outcome of this treatment regimen." @default.
- W70642724 created "2016-06-24" @default.
- W70642724 creator A5013542315 @default.
- W70642724 creator A5028041853 @default.
- W70642724 creator A5035341607 @default.
- W70642724 creator A5042204788 @default.
- W70642724 creator A5065298904 @default.
- W70642724 creator A5066676157 @default.
- W70642724 creator A5074477435 @default.
- W70642724 date "2009-06-10" @default.
- W70642724 modified "2023-09-27" @default.
- W70642724 title "Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide." @default.
- W70642724 doi "https://doi.org/10.3205/000063" @default.
- W70642724 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2716555" @default.
- W70642724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19675744" @default.
- W70642724 hasPublicationYear "2009" @default.
- W70642724 type Work @default.
- W70642724 sameAs 70642724 @default.
- W70642724 citedByCount "2" @default.
- W70642724 countsByYear W706427242012 @default.
- W70642724 crossrefType "journal-article" @default.
- W70642724 hasAuthorship W70642724A5013542315 @default.
- W70642724 hasAuthorship W70642724A5028041853 @default.
- W70642724 hasAuthorship W70642724A5035341607 @default.
- W70642724 hasAuthorship W70642724A5042204788 @default.
- W70642724 hasAuthorship W70642724A5065298904 @default.
- W70642724 hasAuthorship W70642724A5066676157 @default.
- W70642724 hasAuthorship W70642724A5074477435 @default.
- W70642724 hasConcept C121608353 @default.
- W70642724 hasConcept C126322002 @default.
- W70642724 hasConcept C126894567 @default.
- W70642724 hasConcept C141071460 @default.
- W70642724 hasConcept C143998085 @default.
- W70642724 hasConcept C167734588 @default.
- W70642724 hasConcept C203092338 @default.
- W70642724 hasConcept C2776364478 @default.
- W70642724 hasConcept C2777025900 @default.
- W70642724 hasConcept C2777472916 @default.
- W70642724 hasConcept C2777909004 @default.
- W70642724 hasConcept C2779609412 @default.
- W70642724 hasConcept C2780091579 @default.
- W70642724 hasConcept C2780227381 @default.
- W70642724 hasConcept C31760486 @default.
- W70642724 hasConcept C526805850 @default.
- W70642724 hasConcept C535046627 @default.
- W70642724 hasConcept C71924100 @default.
- W70642724 hasConcept C90924648 @default.
- W70642724 hasConceptScore W70642724C121608353 @default.
- W70642724 hasConceptScore W70642724C126322002 @default.
- W70642724 hasConceptScore W70642724C126894567 @default.
- W70642724 hasConceptScore W70642724C141071460 @default.
- W70642724 hasConceptScore W70642724C143998085 @default.
- W70642724 hasConceptScore W70642724C167734588 @default.
- W70642724 hasConceptScore W70642724C203092338 @default.
- W70642724 hasConceptScore W70642724C2776364478 @default.
- W70642724 hasConceptScore W70642724C2777025900 @default.
- W70642724 hasConceptScore W70642724C2777472916 @default.
- W70642724 hasConceptScore W70642724C2777909004 @default.
- W70642724 hasConceptScore W70642724C2779609412 @default.
- W70642724 hasConceptScore W70642724C2780091579 @default.
- W70642724 hasConceptScore W70642724C2780227381 @default.
- W70642724 hasConceptScore W70642724C31760486 @default.
- W70642724 hasConceptScore W70642724C526805850 @default.
- W70642724 hasConceptScore W70642724C535046627 @default.
- W70642724 hasConceptScore W70642724C71924100 @default.
- W70642724 hasConceptScore W70642724C90924648 @default.
- W70642724 hasLocation W706427241 @default.
- W70642724 hasOpenAccess W70642724 @default.
- W70642724 hasPrimaryLocation W706427241 @default.
- W70642724 isParatext "false" @default.
- W70642724 isRetracted "false" @default.
- W70642724 magId "70642724" @default.
- W70642724 workType "article" @default.